Diabetes CareArticle
Comment on Ostrominski et al. Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations.
Diabetes care · ADA · 08/20/2026
Authors: Zhang, Yazhou; Liu, Jianping
Publication types: Letter
PubMed abstract / permitted excerpt
We read with interest the report by Ostrominski et al. ( 1 ), which used two target-trial emulations to compare tirzepatide with dulaglutide or semaglutide among patients with type 2 diabetes and established atherosclerotic cardiovascular disease. The study is timely and carefully constructed. Our concern is not whether a statistical contrast was observed but what that contrast represents: superio
Full-text bodies are not stored. Official ADA RSS plus PubMed. Standards of Care via title/type filters, not scraped HTML.